Glucosio Eurospital

Glucosio Eurospital is a pharmaceutical preparation that contains glucose monohydrate as the active ingredient, supplied as an injectable solution for intravenous administration. Although a specific concentration is not listed, the product is formulated to deliver a sterile aqueous glucose solution suitable for parenteral use. It is marketed in the European Union and is available by prescription for clinical settings that require rapid glucose supplementation in hospital.

Glucosio Eurospital is indicated for conditions where intravenous glucose is required to restore or maintain normal blood sugar levels.

- Treatment of acute hypoglycemia when oral glucose intake is not feasible. - Component of parenteral nutrition regimens for patients unable to receive enteral feeding. - Fluid and electrolyte replacement solutions where additional caloric support is needed. - Support during perioperative periods to prevent intra‑operative hypoglycemia. - Management of metabolic disorders that demand controlled glucose infusion.

Glucosio Eurospital may be associated with a range of adverse reactions, most of which are related to the intravenous administration of a glucose solution.

Common: - Transient hyperglycemia due to rapid infusion of glucose. - Local irritation or pain at the injection site. - Mild electrolyte disturbances such as low potassium levels. - Nausea or vomiting occasionally reported after rapid infusion.

Serious: - Severe hyperglycemia leading to osmotic diuresis or ketoacidosis in susceptible patients. - Allergic reactions including rash, urticaria, or anaphylaxis. - Volume overload causing pulmonary edema in patients with compromised cardiac function. - Severe electrolyte imbalance such as profound hyponatremia in patients receiving large volumes.

When prescribing Glucosio Eurospital, clinicians should consider patient‑specific factors and monitor for potential complications associated with intravenous glucose therapy.

- Assess blood glucose levels before and during infusion to avoid excessive hyperglycemia. - Evaluate cardiac and renal function, as fluid overload may exacerbate heart failure or renal impairment. - Adjust infusion rate in patients with diabetes mellitus or insulin resistance. - Monitor electrolyte concentrations, particularly potassium and sodium, during prolonged administration. - Use aseptic technique to prevent catheter‑related infections. - Consider compatibility with other intravenous solutions to avoid precipitation or incompatibility.

Glucosio Eurospital can interact with other intravenously administered agents, influencing glucose metabolism, fluid balance, or electrolyte status.

Avoid: - Co‑administration with high‑dose insulin infusions without appropriate glucose monitoring, which may precipitate severe hypoglycemia. - Simultaneous infusion of hypertonic dextrose solutions, which can cause excessive plasma glucose concentrations.

Use with caution: - Concurrent use of potassium‑containing IV fluids; rapid glucose infusion may shift potassium intracellularly, risking hypokalemia. - Administration alongside diuretics that affect fluid and electrolyte balance, requiring close monitoring. - Use with catecholamine vasopressors, as glucose can potentiate catecholamine‑induced hyperglycemia. - When combined with glucocorticoids, monitor for additive hyperglycemic effects.